- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00273325
Immunogenicity of PCV-7 Vaccine in VLBW Infants (PCV-7)
Observational Study of the Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Very-low-birth-weight Infants
Přehled studie
Postavení
Detailní popis
Streptococcus pneumoniae causes an estimated 10-25% of all pneumonias in the United States, and is responsible for an estimated 40,000 deaths per year. Invasive pneumococcal disease has a peak incidence of 235/100,000 among children aged 6-11 months. Pneumococcal meningitis carries a higher risk of death (15%) or neurodevelopmental impairment (12-28%) than Hib or Neisseria meningitides.
Premature infants are at a higher risk for invasive disease with Streptococcus pneumoniae. The heptavalent pneumococcal-CRM197 conjugate vaccine (PCV-7) effectively prevents invasive pneumococcal disease in full-term infants, but was been incompletely studied in premature infants. The American Academy of Pediatrics (AAP) recommends that "prematurely born infants, including infants of low birth weight, should be immunized at the usual chronological age in most cases", but cautions that "some studies suggest a reduced immune response in very low-birth-weight infants (<1500 g)."
This observational study assessed the effectiveness of the PCV-7 vaccine to generate a sufficient immune response in a safe manner when given to very low birth weight (VLBW) infants in routine pediatric practice. We hypothesized that among VLBW infants, the frequency of estimated minimum protective antibody titers to PCV-7 (>=0.15 μg/mL) would decrease with decreasing birth weight.
Infants 501-1500g birth weight and <32 0/7 weeks gestational age were enrolled from nine NICHD Neonatal Research Network centers from 2004 to 2006. Enrollment was stratified by weight group to yield approximately 20 infants per 100g increments from 501-1500g birth weight whose primary PCV-7 series was initiated before 3 months and completed by 8 months after birth. The infants' primary providers gave PCV-7 vaccination at 2, 4, and 6 months after birth. Infants had a single 2-ml blood sample drawn 4-6 weeks following the third dose of PCV-7. Antibodies for each of the seven vaccine serotypes included in PCV-7 were measured by enzyme-linked immunosorbent assay. Children were followed until 18-22 months corrected age to assess survival, infection, and neurodevelopmental outcomes.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35233
- University of Alabama at Birmingham
-
-
California
-
Palo Alto, California, Spojené státy, 94304
- Stanford University
-
-
Florida
-
Miami, Florida, Spojené státy, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30303
- Emory University
-
-
Michigan
-
Detroit, Michigan, Spojené státy, 48201
- Wayne State University
-
-
New York
-
Rochester, New York, Spojené státy, 14642
- University of Rochester
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 27157
- Wake Forest University
-
Durham, North Carolina, Spojené státy, 27710
- Duke University
-
Durham, North Carolina, Spojené státy, 27705
- RTI International
-
-
Texas
-
Dallas, Texas, Spojené státy, 75235
- University of Texas Southwestern Medical Center at Dallas
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion criteria
- Gestational age <32 0/7 weeks
- Included in Neonatal Research Network Generic Database
- Family has a telephone at home
- Anticipated availability for blood draw 4-6 weeks following 3rd vaccine dose
- Consent obtained before first dose of PCV-7 is given
Exclusion criteria
- Known immunodeficiency
- HIV exposure
- Parental non-consent
- Primary care pediatrician not willing to participate
- Enrollment in a conflicting trial
- Infant has not received first dose of PCV-7 vaccine by 3 months of age
Studijní plán
Jak je studie koncipována?
Detaily designu
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Serotype 6B pneumococcal capsular polysaccharide antibody >=0.15 μg/ml
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Pneumococcal capsular polysaccharide antibody >=0.15 μg/ml for the other six vaccine serotypes
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Pneumococcal capsular polysaccharide antibodies >=1.0 μg/ml for all seven vaccine serotypes
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Geometric mean titers of pneumococcal capsular polysaccharide antibody to the seven vaccine serotypes
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Pneumococcal capsular polysaccharide antibodies >=0.15 μg/ml and >=1.0 μg/ml, and geometric mean titers of antibody, to the seven vaccine serotypes in children completing the primary series, regardless of postnatal age
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Opsonization of 6B pneumococcal capsular polysaccharide plus 1 low immunogenicity, high prevalence serotype (e.g., 23F) among infants in the lowest quartile of antibody response
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Effect of possible mediating variables on the achievement of levels of serotype 6B pneumococcal capsular polysaccharide antibody >=0.15 μg/ml
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Effect of pneumococcal conjugate immunization status (complete & timely v. complete v. incomplete) on outcome (survival, serious infection, neurodevelopmental outcome) at 18-22 months corrected age in infants <=1000g
Časové okno: 18-22 months corrected age
|
18-22 months corrected age
|
Levels of antibody >=0.15 μg/ml and >=1.0 μg/ml to Hib polyribosylribitol
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Avidity of antibody to Hib-PRP among infants in the lowest quartile of antibody response,regardless of postnatal or gestational age
Časové okno: 4-6 weeks following the third dose of PCV-7
|
4-6 weeks following the third dose of PCV-7
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Shahnaz Duara, MD, University of Miami
- Vrchní vyšetřovatel: Carl T. D'Angio, MD, University of Rochester
Publikace a užitečné odkazy
Obecné publikace
- D'Angio CT, Heyne RJ, O'Shea TM, Schelonka RL, Shankaran S, Duara S, Goldberg RN, Stoll BJ, Van Meurs KP, Vohr BR, Das A, Li L, Burton RL, Hastings B, Phelps DL, Sanchez PJ, Carlo WA, Stevenson DK, Higgins RD; NICHD Neonatal Research Network. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J. 2010 Jul;29(7):600-6. doi: 10.1097/INF.0b013e3181d264a6.
- Wynn JL, Li L, Cotten CM, Phelps DL, Shankaran S, Goldberg RN, Carlo WA, Van Meurs K, Das A, Vohr BR, Higgins RD, Stoll BJ, D'Angio CT. Blood stream infection is associated with altered heptavalent pneumococcal conjugate vaccine immune responses in very low birth weight infants. J Perinatol. 2013 Aug;33(8):613-8. doi: 10.1038/jp.2013.5. Epub 2013 Jan 31.
- Ang JY, Lua JL, Asmar BI, Shankaran S, Heyne RJ, Schelonka RL, Das A, Li L, Jackson DM, Higgins RD, D'Angio CT; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Nasopharyngeal carriage of Streptococcus pneumoniae in very low-birth-weight infants after administration of heptavalent pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med. 2010 Dec;164(12):1173-5. doi: 10.1001/archpediatrics.2010.233. No abstract available.
- D'Angio CT, Murray TE, Li L, Heyne RJ, O'Shea TM, Schelonka RL, Shankaran S, Duara S, Goldberg RN, Stoll BJ, Stevenson DK, Vohr BR, Phelps DL, Carlo WA, Pichichero ME, Das A, Higgins RD; NICHD Neonatal Research Network. Immunogenicity of Haemophilus influenzae type b protein conjugate vaccines in very low birth weight infants. Pediatr Infect Dis J. 2013 Dec;32(12):1400-2. doi: 10.1097/01.inf.0000437263.04493.7c. No abstract available.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
- Pneumokokové vakcíny
- Imunogenicita
- Předčasnost
- Vakcíny, konjugát
- Odpověď na vakcínu
- NICHD síť novorozeneckého výzkumu
- Velmi nízká porodní hmotnost (VLBW)
- Extrémně nízká porodní hmotnost (ELBW)
- Heptavalent pneumococcal conjugate vaccine (PCV-7)
- pneumococcal polysaccharide, type 6B
- Pneumococcal polysaccharide, type 14
- Pneumococcal polysaccharide, type 19F,
- Pneumococcal polysaccharide, 23F
- Pneumococcal polysaccharide, 18C
- Pneumococcal polysaccharide, 4
- Pneumococcal polysaccharide, 9V
Další relevantní podmínky MeSH
Další identifikační čísla studie
- NICHD-NRN-0031
- M01RR000633 (Grant/smlouva NIH USA)
- UL1RR024982 (Grant/smlouva NIH USA)
- U10HD021385 (Grant/smlouva NIH USA)
- U10HD027851 (Grant/smlouva NIH USA)
- U10HD027880 (Grant/smlouva NIH USA)
- U10HD034216 (Grant/smlouva NIH USA)
- U10HD040492 (Grant/smlouva NIH USA)
- U10HD040689 (Grant/smlouva NIH USA)
- UL1RR025744 (Grant/smlouva NIH USA)
- M01RR000070 (Grant/smlouva NIH USA)
- U10HD021397 (Grant/smlouva NIH USA)
- U10HD040498 (Grant/smlouva NIH USA)
- U10HD040521 (Grant/smlouva NIH USA)
- M01RR000032 (Grant/smlouva NIH USA)
- M01RR000039 (Grant/smlouva NIH USA)
- M01RR000044 (Grant/smlouva NIH USA)
- M01RR007122 (Grant/smlouva NIH USA)
- M01RR016587 (Grant/smlouva NIH USA)
- UL1RR025777 (Grant/smlouva NIH USA)
- UL1RR025008 (Grant/smlouva NIH USA)
- M01RR000030 (Grant/smlouva NIH USA)
- U01HD036790 (Grant/smlouva NIH USA)
- UL1RR024160 (Grant/smlouva NIH USA)
- UL1RR024128 (Grant/smlouva NIH USA)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Pneumokokové infekce
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Oswaldo Cruz InstituteZatím nenabírámeMalomocenstvíBrazílie
-
Institute of Tropical Medicine, BelgiumLeiden University Medical Center; Damien Foundation; Instituto Fernandes Figueira a další spolupracovníciDokončenoMalomocenstvíKomory, Madagaskar
-
Institute of Tropical Medicine, BelgiumDamien Foundation; Instituto Oswaldo Cruz; Programme National de lutte contre... a další spolupracovníciDokončeno
-
Coordenação de Aperfeiçoamento de Pessoal de Nível...Dokončeno
-
Kaiser PermanenteHealth Resources and Services Administration (HRSA)Již není k dispozici
-
National Institute of Allergy and Infectious Diseases...Dokončeno
-
Annemieke GelukThe Leprosy Mission BangladeshNábor
-
Institute of Tropical Medicine, BelgiumNábor
-
Emory UniversityDokončenoCentral Line Associated Bloodstream Infections (CLABSI) | Transplantace kostní dřeněSpojené státy
-
IDRIAmerican Leprosy MissionsDokončeno